Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Revenue of Shattuck Labs, Inc. (STTK)
Revenue in 2023 (TTM): $1.66 M
According to Shattuck Labs, Inc.'s latest financial reports the company's current revenue (TTM) is $1.66 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Shattuck Labs, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $1.66 M | $-2,385,000 | $-87,915,000 | $-87,298,000 | $-87,298,000 |
| 2022 | $652 K | $-2,723,000 | $-103,329,000 | $-101,945,000 | $-100,561,000 |
| 2021 | $30.02 M | $28.64 M | $-43,889,000 | $-44,974,000 | $-44,349,000 |
| 2020 | $9.93 M | $-27,549,000 | $-36,931,000 | $-36,603,000 | $-35,436,000 |
| 2019 | $9.89 M | $-19,114,000 | $-23,445,000 | $-23,982,000 | $-23,883,000 |
| 2018 | $22.44 M | $-2,365,000 | $-5,284,000 | $-7,388,000 | $-7,388,000 |